Being diagnosed with advanced metastatic pancreatic cancer was a grim experience for Steve Price. But thanks to his doctors at Weill Cornell Medicine and NewYork-Presbyterian, state-of-the-art interventional radiology allowed him to receive chemotherapy immediately after biopsy, shrinking his tumors dramatically. Then, a precision medicine clinical trial revealed that Price had a mutation in the BRCA1 gene, normally associated with breast cancer. By examining his unique genetic profile, Price’s medical team was able to determine that a new therapy targeting the mutation could give him his life back.
December 14, 2018